Spate Of Late-Stage DLBCL Trial Failures Leaves Spoils Waiting
Executive Summary
A run of bad luck for developers of potential treatments for diffuse large B-cell lymphoma – Roche, Celgene and Novartis – has withered the late-stage pipeline for an indication that has long been in need of new therapies. Scrip and Datamonitor Healthcare take a look at what's next for the disease.
You may also be interested in...
AbbVie, J&J's Imbruvica Has Rare, But Not Surprising Failure In DLBCL
Analysts generally were not surprised that Imbruvica plus R-CHOP did not provide a significant benefit versus R-CHOP alone in a hard-to-treat type of non-Hodgkin lymphoma. The failure leaves an opening for competitors, such as Celgene's Revlimid, which will soon have data in this indication.
Amgen's Cancer Strategy: A Multitude Of Modalities In Immuno-Oncology And Beyond
Amgen is the leader in approved bispecific antibodies and oncolytic viruses, but the company's not shy about expanding its oncology pipeline with even more modes of delivering medicines to cancer patients.
Blow For Celgene As Revlimid Trial Miss Removes Blockbuster Indication
Celgene Corp.'s hopes of extending the market reach of its blockbuster oncology therapy Revlimid (lenalidomide) have taken a blow as Phase III data for the drug in elderly diffuse large B-cell lymphoma (DLBCL) patients have failed to show benefit on overall survival.